BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 2942242)

  • 1. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
    Rosenblum MG; Maxwell BL; Talpaz M; Kelleher PJ; McCredie KB; Gutterman JU
    Cancer Res; 1986 Sep; 46(9):4848-52. PubMed ID: 2942242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy.
    Maxwell BL; Talpaz M; Gutterman JU
    Int J Cancer; 1985 Jul; 36(1):23-8. PubMed ID: 3160669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-interferon receptors in malignant B-cells from patients with chronic lymphocytic leukemia: relation to induction of 2'-5'-oligoadenylate synthetase and blast transformation.
    Ostlund L; Grandér D; Juliusson G; Robèrt KH; Lundgren E; Einhorn S
    Cancer Res; 1989 Jun; 49(12):3425-30. PubMed ID: 2524252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
    Rosenblum MG; Yung WK; Kelleher PJ; Ruzicka F; Steck PA; Borden EC
    J Interferon Res; 1990 Apr; 10(2):141-51. PubMed ID: 2140395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific residues within an amino-terminal domain of 35 residues of interferon alpha are responsible for recognition of the human interferon alpha cell receptor and for triggering biological effects.
    Shafferman A; Velan B; Cohen S; Leitner M; Grosfeld H
    J Biol Chem; 1987 May; 262(13):6227-37. PubMed ID: 2952649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-induced 2'-5' oligoadenylate synthetase during interferon-alpha therapy in homosexual men with Kaposi's sarcoma: marked deficiency in biochemical response to interferon in patients with acquired immunodeficiency syndrome.
    Preble OT; Rook AH; Steis R; Silverman RH; Krause D; Quinnan GV; Masur H; Jacob J; Longo D; Gelmann EP
    J Infect Dis; 1985 Sep; 152(3):457-65. PubMed ID: 2993441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of interferon-alpha on hairy cell leukemia: expression of specific receptors and (2'-5')oligo (A) synthetase in tumor cells from sensitive and resistant patients.
    Billard C; Ferbus D; Sigaux F; Castaigne S; Degos L; Flandrin G; Falcoff E
    Leuk Res; 1988; 12(1):11-8. PubMed ID: 2965776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons-alpha/beta- and -gamma-resistant Friend cell variants exhibiting receptor sites for interferons but no induction of 2-5A synthetase and 67K protein kinase.
    Coccia EM; Federico M; Romeo G; Affabris E; Cofano F; Rossi GB
    J Interferon Res; 1988 Feb; 8(1):113-27. PubMed ID: 2966842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.
    Merritt JA; Meltzer DM; Ball LA; Borden EC
    Prog Clin Biol Res; 1985; 202():423-30. PubMed ID: 3832076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2',5'-Oligoadenylate synthetase activity in peripheral blood lymphocytes as a clinical marker in interferon therapy for chronic hepatitis B.
    Furuta M; Akashi K; Nakamura Y; Matsumoto K; Yamaguchi H; Takamatsu S; Shimizu T
    J Interferon Res; 1987 Feb; 7(1):111-9. PubMed ID: 3585079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
    Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
    Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
    Moritz T; Weissmann B; Grünewald B; Hust H; Kummer G; Niederle N
    Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro.
    Estrov Z; Lau AS; Williams BR; Freedman MH
    Exp Hematol; 1987 Feb; 15(2):127-32. PubMed ID: 3102273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon.
    Nakajima S; Kuroki T; Shintani M; Kurai O; Takeda T; Nishiguchi S; Shiomi S; Seki S; Kobayashi K
    Hepatology; 1990 Dec; 12(6):1261-5. PubMed ID: 2147916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2.
    Freedman MH; Estrov Z; Williams BR; Gelfand EW
    Am J Pediatr Hematol Oncol; 1986; 8(3):178-82. PubMed ID: 3766908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro.
    Ruzicka FJ; Schmid SM; Groveman DS; Cummings KB; Borden EC
    Cancer Res; 1987 Sep; 47(17):4582-9. PubMed ID: 2957045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic expression of 2-5A synthetase in myeloid cells induces growth arrest and facilitates the appearance of a myeloid differentiation marker.
    Salzberg S; Hyman T; Turm H; Kinar Y; Schwartz Y; Nir U; Lejbkowicz F; Huberman E
    Cancer Res; 1997 Jul; 57(13):2732-40. PubMed ID: 9205084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
    Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
    J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages.
    Witt PL; Spear GT; Helgeson DO; Lindstrom MJ; Smalley RV; Borden EC
    J Interferon Res; 1990 Aug; 10(4):393-402. PubMed ID: 2121851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route.
    Rosenblum MG; Riso A; Gutterman JU
    Cancer Chemother Pharmacol; 1986; 16(3):273-6. PubMed ID: 3084109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.